Accumetrics,
Inc. |
|
2011 ACCF/AHA Guidelines Incorporate New
Recommendations for Platelet Reactivity Testing
Accumetrics
Announces Publication of GRAVITAS Primary Results in JAMA
Accumetrics Closes 2010 With Positive Outlook
Accumetrics,
Inc. Forms Partnership with Grifols as Its Distributor in
Spain, Portugal and Chile
Accumetrics, Inc. Announces
GRAVITAS Trial 50 Percent Enrolled
Accumetrics,
Inc. Announces Distribution Channels in Israel and Cyprus
back to top |
Alereon, Inc. |
|
Ultrawideband: Down, But Far From Out
WiMedia and UWB: where to from here?
Alereon Receives FCC Modular Certification for Worldwide
Wireless USB Half-MiniCard
back to top |
Apollo Endosurgery,
Inc. |
|
Apollo Endosurgery® Signs Agreement with Apollo Hospitals Group to Advance Incisionless Bariatric Surgery in India
Apollo Endosurgery Announces First Incisionless
Full-thickness Resection of a Colonic Polyp
Apollo Endosurgery Taps Michael Doty for CFO
New Class of Instruments for Flexible Surgery from
Apollo Endosurgery Used in Cancer Therapy
Apollo Endosurgery Demonstrates Clinical Functionality of
the Newly Launched OverStitch™
Apollo Endosurgery Completes First-in-Human Cases with New
OverStich™
Three
Austin Companies Get Cancer Research Grants
Most
Successful U.S. Startups 2008: Apollo Endosurgery -
BusinessWeek
Surgery Without the Slicing
back to top |
| Asuragen,
Inc. |
|
Results from Study Show microRNA-based Pancreatic Cancer Assay Improves the Diagnostic Accuracy of FNA Cytology
Asuragen announces launch of InformTM Thyroid
Panel
Asuragen Reports Results from a Multi-Center Study on
Fragile X Gene
Asuragen Announces New Notices of Allowance from USPTO
Related to the Diagnostic Applications of Cancer-Related
miRNAs
Johns Hopkins Researchers Publish Results of Study
Evaluating Multiplex Assay for Detection of Common NPM1
Mutations
Asuragen's
Ground Breaking Research Funded with Help from Grants
Program
Asuragen
Appoints French Distributor Biomedical Diagnostics SA for
Signature Oncology Portfolio
Mirna
Therapeutics Announces Dr. Frank Slack as Scientific Advisor
Gov. Perry Announces $5
Million Investment in Development, Commercialization of
Cancer Treatment
back to top
|
| BioForm
Medical, Inc. (NASDAQ: BFRM) - Acquired by: Merz |
|
Merz to Acquire BioForm Medical
back to top
|
| BioMimetic
Pharmaceuticals, Inc. ("BMTI") (NASDAQ: BMTI) |
BioMimetic Therapeutics, Inc. to Highlight Commercial and
Product Development Activities during AAOS
BioMimetic Therapeutics Announces Date of FDA Advisory Panel
Review of Augment(TM) Bone Graft
BioMimetic Therapeutics PMA Remains on Track
BioMimetic nears European
patent on tissue healing products
Dr. Samuel E. Lynch Presides Over the NASDAQ
Closing Bell to Celebrate
the Initial Public Offering of BioMimetic Therapeutics, Inc. [BMTI]
back
to top |
| BioSurface
Engineering
Technologies,
Inc. ("BioSET") |
|
Brookhaven Lab and BioSET, Inc., Patent a Synthetic Peptide
That Enhances Bone Growth
BioSET Announces Initiation Of Clinical Trials For AMPLEX
Osteo-Promotive Bone Graft System For Spine Fusion
Tornier and Bioset Enter Synthetic Growth Factor Pact
back
to top
|
| Cameron Health, Inc. |
|
Cameron Health Reaches 1,000 Patient Milestone For S-ICD® System
Cameron Health Completes Enrollment in Pivotal FDA Clinical
Study of the
S-ICD® System
Cameron Health Announces Launch of EFFORTLESS S-ICD Registry
to Capture Long-Term Outcomes of S-ICD® System
Cameron Health Appoints Seasoned Execuitve as Chief
Financial Officer
Entirely Subcutaneous ICD Eliminates Need For Transvenous Lead Wires
Cameron Health, Inc. Appoints Kevin Hykes President and
Chief Executive Officer
The rhythm of life
back
to top |
| Cardiva Medical, Inc. |
|
Cardiva Medical, Inc. Announces U.S. Distribution for
Hemostasis Products
Cardiva
Medical, Inc. Announces Appointment of Charles Maroney,
President and Chief Executive Officer
Cardiva Medical, Inc. Receives FDA Clearance for the
Catalyst III System
Cardiva Medical, Inc. Announces Presentation at the 2008 UBS
Global Life Science Conference
back
to top
|
| GlycoMimetics,
Inc. ("GMI") |
|
GlycoMimetics, Inc. Attracts $38
Million in Latest Venture Round
New Drug to
Treat Sickle Cell Crisis Begins Pilot Study in Patients
GlycoMimetics, Inc. Awarded NIH Grant to Study Drug
Candidate in Diabetes
GlycoMimetics, Inc. Completes Phase 1 Clinical Studies
of Lead Drug Candidate
back to top |
| IDEV
Technologies, Inc. |
|
IDEV Technologies Receives FDA Clearance for its SUPERA VERITAS® 6 French Stent Delivery
IDEV Technologies Launches Lower Profile SUPERA VERITAS®
Stent Delivery System
IDEV Technologies Announces Completion of SUPERB Clinical
Trial Enrollment
SUPERA VERITAS®
Receives Regulatory Approval in Australia
One-Year European Registry Data Released for Popliteal
Stenting with SUPERA®
Long Term European Data Released for SUPERA® Stent from IDEV
Technologies
IDEV
Technologies
Names Veteran Healthcare Executive Dennis Donohoe, M.D.
Chief Medical Officer
IDEV
Technologies Introduces SUPERA VERITAS™ Stent
Delivery System in Europe
IDEV
Technologies Names Christopher M. Owens President, Chief
Executive Officer
IDEV
Technologies Announces First Patient Enrolled in
Multi-Center Clinical Trial of SUPERA Peripheral Stent
back to top |
| InSite
Vision, Inc. ("ISV") (INSV.OB) |
|
InSite Vision Announces Positive Phase 2 PK Results for BromSite(TM) (ISV-303) for the Reduction of Pain and Inflammation After Cataract Surgery
InSite Vision Receives Special Protocol Assessment from the
FDA for the DOUBle Phase 3 Clinical Trial of AzaSite
Plus(TM) and DexaSite(TM)
InSite Vision Completes Patient Enrollment in ISV-303 Phase
1/2 Clinical Study for Post-Surgical Ocular Pain and
Swelling
InSite Vision Names Timothy Ruane Chief Executive Officer
InSite Vision Signs International Licensing and Distribution
Agreement for AzaSite((R)) in Japan and Taiwan With Nitten
Pharmaceutical Co., Ltd
InSite Vision Receives Regulatory Approval for AzaSite® in
Canada
InSite Vision Announces Restructuring to Support 2009
Strategic Priorities
back to top |
|
Intersect ENT, Inc. (formerly Sinexus) |
|
Intersect ENT Announces Positive Data from Pivotal Study of
Propel Implant
Intersect ENT Announces U.S. FDA Approval for First Drug
Releasing Implant for Chronic Sinusitis Patients
Intersect ENT Closes Series C Financing, Recognized for
Clinical Science
Sinexus Changes Name to Intersect ENT, Initiates Pivotal
Study
back
to top
|
| LDR
Spine USA, Inc. ("LDR") |
|
LDR Opens New and Expanded Global Headquarters in Austin, Texas
LDR receives approval to market two new stand-alone spine products in China
LDR Announces FDA Clearance of the ROI-A® Oblique ALIF Cage
LDR Founder, President and CEO Named a 2011 Ernst & Young
Entrepreneur Of The Year®
for the Central Texas Region
Two-Level Mobi-C®
Cervical Artificial Disc PMA Submitted by LDR
LDR reports 77% sales growth for US operations, 45% global
operations, 2010 over prior year
LDR Submits PMA for MOBI-C® Cervical Artificial
Disc
1st Mobi-C® cervical artificial disc implanted in China
LDR Announces FDA Clearance of its ROI-A™ ALIF Device
back
to top |
| Mirna
Therpeutics, Inc. |
Mirna Therapeutics to Moderate Session on Promise of miRNAs
in Cancer at BIO International Convention
Mirna Therapeutics and Collaborators Publish New Data on
miR-34 and its Role in Cancer Stem Cells
Mirna
Therapeutics reports notice of allowance from USPTO related
to the clinical application of an important cancer-related
miRNA
Mirna
Therapeutics recommended for $10 million commercialization
award from the Cancer Prevention and Research Institute of
Texas
back
to top |
| On-X® Life Technologies, Inc. |
|
On-X LTI Receives FDA Approval for Aortic Valve with
Vascutek Graft
On-X Life Technologies Doubles Manufacturing Space in Austin
Examination of
hemolytic potential with the On-X® prosthetic heart valve
Austin-Based Medical Carbon Research Institute, LLC. Becomes On-X Life
Technologies, Inc.
back
to top |
| Ortho
Kinematics, Inc. |
|
KineGraph
Study: Finding the Right Patient
Kinegraph
VMA™ (Vertebral Motion Analyzer) Video
Gov. Perry: We Must Invest Wisely to Help Texans and
Strengthen Our Economy
back
to top
|
| OsteoBiologics,
Inc. ("OBI")
- Acquired by: Smith & Nephew |
Smith &
Nephew Acquires OBI, Inc.
back
to top |
Tryton Medical, Inc. |
|
IVUS Cohort Recruitment Complete in Landmark Tryton IDE Study
Tryton Announces Positive Data from Three European
Registries
Shawn P. McCarthy Appointed President and CEO of Tryton
Medical
Tryton Announces Enrollment of First U.S. Patient in Pivotal
Study of Side Branch Stent
Tryton Announces Investigational Device Exemption
Conditional Approval from FDA
TRYTON Announces Registry
Evaluating Tryton Stent System for Left Main Disease and
Celebrates 500th Implant
Tryton
Celebrates 250th Implant of Innovative Side Branch Stent
System
Tryton
Announces First Patient Enrollment in E-Tryton 150 Registry
Tryton Medical introduces Side Branch Stent System in Europe
back
to top
|
| ZIOPHARM Oncology, Inc. (NASDAQ:
ZIOP) |
|
ZIOPHARM Presents Positive
Darinaparsin Clinical Data at ASCO's Prestigious Clinical
Science Symposium
ZIOPHARM Presents Positive
Data from Phase I Study of Palifosfamide in Combination with
Doxorubicin at ASCO
ZIOPHARM
Presents Positive Indibulin Translationaland Dose Scheduling
Data at ASCO
back
to top |
| |
| |
| For Media
Assistance, please contact
Brooke Akins at
512.542.0010. |
|
